News / Taiwan / economic_daily
Apexigen Reports 19x Monthly Revenue Surge on China Drug Milestone
Health Technology · Pharmaceuticals: Major · economic_daily · 2026-11-09
6576
Apexigen's October revenue jumped significantly due to milestone payments from its prostate cancer drug CAMCEVI receiving regulatory approval in China.
What Happened
Revenue Performance: Apexigen announced October consolidated revenue of approximately NT$125 million, marking a 1,895.4% increase from the previous month, with year-to-date revenue up 11.4%.
Revenue Drivers: The surge was primarily driven by a NT$117 million milestone payment from the NMPA approval of CAMCEVI in China, alongside ongoing sales royalties from the US and Europe.
China Strategy: The company has exclusively licensed CAMCEVI to GeneScience Pharmaceuticals for various indications, including prostate cancer and breast cancer, with the latter currently under regulatory review.
Global Expansion: Commercial sales have commenced in Germany via partner Accord Healthcare, while the company continues to prepare for broader product launches in the US market.